דף הבית

חדשות ודיווחים

אירועים כנסים ופעילויות

כנס WFH מאי 2018 בגלזגו

בעריכת: חיים וייסמןcwaisman@netvision.net.il

שלום לכולם,

ליקטתי (מפרסומי "העיתון היומי" של WFH בכנס https://news.wfh.org/category/congress-daily-2018/ -2018/) עבור כולנו משפטים, פסקאות "מפתח" חשובות ומכוננות שניתן ללמוד מהן רבות.

נלקח מתוך הרצאות שניתנו במהלך הכנס העולמי להמופיליה ומחלות דמם נוספות. כנס שנערך בגלזגו על ידי ה WFH. אינני מציין מי המרצה כיוון שכל הנואמים חשובים ובעלי רקע מכובד בתחום. ההדגשות הן שלי ואינן מחייבות. כל המעוניין בהסבר נוסף בעברית, מוזמן לפנות אלי במייל חוזר ולציין באיזו פיסקה מדובר. אשתדל להשיב תשובה נכונה.

מצורפים: - תוצאות ניסויים קליניים בהמליברה לחסרי ולבעלי נוגדן , פורסמו בכנס - תקצירי הרצאות שהוגשו לכנס

חיים וייסמן

הנושא	נפח	קישור לקובץ
R&D Conference Call(WFH 2018)HAVEN 3 _WFH2018pdfstudy / HAVEN 4 study results	962Kb	e180522RD_WFH2018pdf
Abstract	5776Kb	2018-Haemophilia.pdf
מצגת משקפיו של פרופ' מידורי שימה בכנס WFH 2018	953Kb	midurishima-WFH2018.pps

Frank Schnabel, the founder of the World Federation of Hemophilia (WFH), opened the first WFH Congress on June 25, 1963, with these words: ג€�The threat to the life of just one haemophiliac would be sufficient reason for us to travel to this meeting. We are here, however, to help the hundreds of thousands of haemophiliacs by adding another organization which can be instrumental, in liaison with national societies.ג€� Over 50 years later, these words still ring true. The WFH is still focused on the idea of a community of people of action working to help the bleeding disorders community. This is the reason why thousands of people will come together in the name of Treatment for All at the WFH 2018 World Congress in Glasgow, Scotland, this May. By supporting our Congress, participants will be a community of actionג€”and helping to back the many WFH-led programs that are shaping the evolution of bleeding disorders care. As a global federation, the WFH needs to have a wide range of programs in order to support the many needs of the bleeding disorders community. Our programs cover government support, care delivery, medical expertise, distribution of donated treatment products, patient organization data collection, and outcomes research. The idea is that help is need in many ideas, so we need to invest our time and energy in many areas. This approach has allowed us to develop many programs that have helped to make a difference in our community, such as the Cornerstone Initiative, our many Country Programs, the Global Alliance for Progress (GAP), the Twinning Program, the IHTC Fellowship Program, NMO Training, IEQAS, and, of course, the Humanitarian Aid Program. These efforts have delivered measurable results. In 2016, WFH healthcare development programs and activities reached a total of 122 countries worldwide. From January to June 2017 alone, the Humanitarian Aid program was instrumental in delivering 97 million IUs of donated treatment products to people in need. The WFH Congress is where stakeholders come together in the same place to help guide the decisions that will lead to future solutions. Be part of discussions that will impact the future of the bleeding disorders community. By attending the Congress, youג€™re supporting WFH programs, and joining a team of people who want to play an active role in the evolving world of bleeding disorders care. The many talks that happen during Congress are an opportunity for participants to learn about new developments in the industry and how they will impact the community. This is the way to have your voice heard. -------------------------------------------------------------------------------------------- Weג€™ve moved from on-demand to prophylactic treatment with ever-increasing durations (of efficacy), and now to 24/7 coverage with gene therapy and novel agents Glenn Pierce discussed a framework for establishing a gene therapy knowledge base, including known unknowns, such as high variability of protein production and the consequences of integrating DNA into the genome Glenn Pierce briefly touched upon gene editing and cell therapy, and showed data demonstrating the feasibility of these technologies Gene therapy is really exciting. Since 2015 weג€™ve seen therapeutic levels of factor IX and factor VIII being achieved in a small number of patients, and those levels have relieved them of their dependence on exogenous replacement therapy In gene therapy, we really need to continue research. There are far too many unanswered questions. We shouldnג€™t forget that this is an early technology Prophylaxis is currently the gold standard for hemophilia treatment The earlier it is started the better the results, but the complexity of prophylaxis may influence adherence to treatment Extended half-life (EHL) products have shown the potential to overcome this problem. Real-world clinical evidence of prophylaxis with factor VIII (FVIII) EHL products indicates that 30 to 40 per cent less infusions are necessary, which equates to 20 to 30 per cent lower consumption of FVIII. For factor XI (FIX) EHL products, the data are even more promising with 55 to 65 per cent less infusions necessary, equating to 40 to 60 per cent lower FIX consumption A move towards personalized medicine will increase treatment complexity, because it will be necessary to identify the correct product, patient, dosing and timing The latest FVIII products may show differential immunogenicity due to new non-wild-type amino acid sequences and non-wild-type post-translational modification a 20 to 43 per cent incidence of inhibitors has been reported in trials of previously untreated patients receiving standard recombinant FVIII products Of an estimated 490,000 people living with hemophilia worldwide, 57,000 receive more than 4 international units (IU) per capita treatment. To treat this population would require 40 billion IU per year. To provide prophylaxis to 10 per cent trough levels would require 792 billion IU per year -------------------------------------------------------------------------------------------- Extended half-life (EHL) products have the potential to reduce the frequency of infusions required to maintain factor to the trough levels achieved with standard half-life products Pasi highlighted the potential safety issue with PEGylated proteins in EHL treatments. ג€�Polyethylene glycol (PEG) is generally not easily biodegradable, it is either metabolized by oxidization of alcohol groups or by urinary clearance,ג€� stated Pasi. ג€�Metabolism by these mechanisms can in theory pose toxicity problems.ג€� However, PEG has a large therapeutic index and there have not been any safety signals in clinical trials to strongly suggest cause for concern. Emerging therapies such as bispecific antibodies, RNA silencing therapy, anti-tissue factor pathway inhibitor and gene therapy will completely change the market again One of the biggest problems facing women with a bleeding disorder is heavy menstrual bleeding affecting nine out of ten women. In addition, women with a bleeding disorder tend to bleed for longer and experience heavier bleeding Many treatment options are available to women with heavy menstrual bleeding. However, barriers to accessing healthcare exist for these women, in part due to reluctance to accept their condition or to approach their doctor about this health issue Certain cultures and religions impose many restrictions on women who are menstruating because they are viewed as impure. However, some societiesג€”such as the Maori society in New Zealand and some North American tribesג€”consider menstruation to be sacred -------------------------------------------------------------------------------------------- Patients want a normal life, healthcare providers aim to optimize treatment and payers work towards reducing costs ultrasound and magnetic resonance imaging techniques are increasingly used to detect changes in the synovium and cartilage in the absence of bleeding. The future looks bright for hemophilia prophylaxis has brought great advances in the treatment of hemophilia, particularly severe cases in which an increase in trough level to two or three per cent results in a dramatic reduction in bleeding the need for treatment to be individualized according to age. There is pharmacokinetic variability between products, so you must take this into account and dose accordingly up-and-coming therapies, including the promising drugs emicizumab and fitusiran, both of which are in clinical development. The subcutaneous route of administration of these drugs will further facilitate treatment, and the recent explosion of new products for hemophilia will make it easier to individualize treatment and lower the disease burden. the exciting area of gene therapy, focusing on two recently published early-stage clinical trials of gene therapy in hemophilia A and B. These trials demonstrate that gene therapy brings about sustainable levels of factor VIII and factor IX. However, immune response to the adeno-associated viral vector remains an issue for the majority of patients and therefore alternatives are needed ג€¦he (WFH president) implored pharmaceutical companies to not allow legal feuds hinder access to innovative treatmentג€¦ Hemophilia is a brand name! VWD and other rare bleeding disorders need the same level of exposure, because no one with a rare bleeding disorder should have to make tough decisions ------------------------------------------------------------------------------------------------------------------------- gene therapy for people with hemophilia include interpatient variation in factor expression, response durability, safety considerations and risk of inhibitor development. Whether the procedure is applicable to children, people with inhibitors, and/or those with a preexisting immunity to the adenovirus-associated viral vector (AAV), including people who already received gene therapy for hemophilia, still needs to be addressed. Mechanisms to enhance factor IX expression are being explored for hemophilia B. Methods include adding a promoter, modifying the vector to remain undetected by the immune system, and incorporating the highly active Padua variant of factor IX. ג€�Gene therapy is more challenging for hemophilia A due to bottlenecks of factor VIII production at the transcriptional, translational and post-translational level,ג€� said VandenDriessche. However, a pivotal clinical trial using codon-optimized AAV serotype 5 recently published promising results in men with severe hemophilia A. VandenDriessche ended the session on lentiviral vectors, a promising technology with several improvements over AAV. Current lentiviral vectors have the potential to sustain factor expression long-term since these are liver-directed therapies and pre-existing immunity is not an issue.